Workflow
Cumberland Pharmaceuticals(CPIX) - 2025 Q1 - Quarterly Results
CPIXCumberland Pharmaceuticals(CPIX)2025-05-06 21:02

Financial Performance - Cumberland Pharmaceuticals reported net revenues of 11.7millionforQ12025,representinga3811.7 million for Q1 2025, representing a 38% increase compared to the same period last year[1]. - The company generated a net profit of 1.3 million and adjusted earnings of 2.4million,equatingto2.4 million, equating to 0.16 per share[7]. - Total operating expenses for the quarter were 10.4million,leadingtoacashflowfromoperationsof10.4 million, leading to a cash flow from operations of 3.9 million[1][7]. - Net revenues for the three months ended March 31, 2025, were 11,713,055,a38.811,713,055, a 38.8% increase from 8,497,701 in the same period of 2024[29]. - Operating income for Q1 2025 was 1,291,947,comparedtoanoperatinglossof1,291,947, compared to an operating loss of (1,869,250) in Q1 2024[29]. - Net income attributable to common shareholders for Q1 2025 was 1,257,068,asignificantrecoveryfromanetlossof1,257,068, a significant recovery from a net loss of (1,946,263) in Q1 2024[29]. - Earnings per share attributable to common shareholders was 0.08forQ12025,comparedtoalossof0.08 for Q1 2025, compared to a loss of (0.14) in Q1 2024[29]. - Cash flows from operating activities provided 3,898,517inQ12025,contrastingwithcashusedof3,898,517 in Q1 2025, contrasting with cash used of (2,136,647) in Q1 2024[31]. - Adjusted earnings for Q1 2025 were 2,397,743,withadjusteddilutedearningspershareof2,397,743, with adjusted diluted earnings per share of 0.16, compared to adjusted loss of (639,811)and(639,811) and (0.05) per share in Q1 2024[33]. Assets and Liabilities - Cumberland ended the quarter with approximately 70millionintotalassets,70 million in total assets, 41.6 million in liabilities, and 28.7millioninshareholders′equity[2][8].−Totalshareholders′equityincreasedto28.7 million in shareholders' equity[2][8]. - Total shareholders' equity increased to 28.7 million as of March 31, 2025, up from 22.9millionattheendof2024[8][27].−Thecompanyreportedanetcashdecreaseof22.9 million at the end of 2024[8][27]. - The company reported a net cash decrease of (2,855,771) in cash and cash equivalents for Q1 2025, down from 18,321,624atthebeginningoftheperiod[31].ProductDevelopmentandRegulatoryApprovals−ThePhaseIIstudyofifetrobanforDuchennemusculardystrophy(DMD)yieldedpositivetop−lineresults,markingasignificantbreakthroughforpatients[3].−VibativreceivedregulatoryapprovalinChina,allowingCumberlandtoentertheworld′ssecond−largestpharmaceuticalmarket,withaproductlaunchexpectedbyyear−end[6].−Thecompanyplanstoconductfurtherdataanalysisandprepareforanend−of−Phase−IImeetingwiththeFDAregardingtheDMDprogram[5].−Cumberland′sproductportfolioincludesKristalose(18,321,624 at the beginning of the period[31]. Product Development and Regulatory Approvals - The Phase II study of ifetroban for Duchenne muscular dystrophy (DMD) yielded positive top-line results, marking a significant breakthrough for patients[3]. - Vibativ received regulatory approval in China, allowing Cumberland to enter the world's second-largest pharmaceutical market, with a product launch expected by year-end[6]. - The company plans to conduct further data analysis and prepare for an end-of-Phase-II meeting with the FDA regarding the DMD program[5]. - Cumberland's product portfolio includes Kristalose (3.5 million), Sancuso (2.3million),Vibativ(2.3 million), Vibativ (1.4 million), and Caldolor (1.3million)inQ12025[7].FutureOutlook−Thecompanyisoptimisticaboutfuturegrowthdrivenbystrongperformancefromapprovedbrandsandpotentialstrategicacquisitions[3].−Thecompanymadeanetinvestmentof1.3 million) in Q1 2025[7]. Future Outlook - The company is optimistic about future growth driven by strong performance from approved brands and potential strategic acquisitions[3]. - The company made a net investment of (1,162,357) in a manufacturing facility during Q1 2025[31]. - Proceeds from an ATM offering in Q1 2025 amounted to $5,266,334, contributing to financing activities[31]. - The weighted-average shares outstanding for diluted earnings in Q1 2025 were 15,259,824, compared to 14,098,022 in Q1 2024[33].